

AD_____

AWARD NUMBER: W81XWH-09-1-0122

TITLE: Identification of Genes Required for the Survival of BRCA 1-/- Cells

PRINCIPAL INVESTIGATOR: Stephen J. Elledge, Ph.D.

CONTRACTING ORGANIZATION: Brigham & Women's Hospital
Boston, MA 02115

REPORT DATE: February 2010

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				<i>Form Approved</i> OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE 1 February 2010		2. REPORT TYPE Annual		3. DATES COVERED 1 Feb 2009 – 31 Jan 2010	
4. TITLE AND SUBTITLE Identification of Genes Required for the Survival of BRCA 1/- Cells				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-09-1-0122	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Stephen J. Elledge, Ph.D. E-Mail: selledge@genetics.med.harvard.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Brigham & Women's Hospital Boston, MA 02115				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT A major obstacle for breast cancer drug discovery is target identification. Despite the wealth of information on copy number alterations and mutations recently available from sequencing efforts such as The Cancer Genome Atlas, identifying new targets for breast cancer therapeutics has proved challenging because causative perturbations cannot be determined from benign changes without functional studies. Genetic shRNA screens are powerful tools for identifying loss-of-function phenotypes in mammalian cells and can be used to complement sequencing efforts in the identification of new drug targets. To perform such screens, we have developed bar-coded shRNA libraries in retroviral and lentiviral vectors that target the entire human genome. Our proposal aims to use this novel screening technology to identify new therapeutic targets for breast cancers harboring BRCA1 mutations. Towards this end, we aim to identify and characterize genes that are selectively required for proliferation and survival of breast cancer cells with BRCA1 loss-of-function mutations but not required for viability of isogenic breast cancer cells expressing wild-type, functional BRCA1. These genes, called BSLs for BRCA1 Synthetic Lethal genes, are essential in cells lacking BRCA1, and as such are prime targets for therapeutic intervention to treat breast cancers that harbor a loss of BRCA1 function. We have accomplished the isolation of isogenic cell lines that differ only in their BRCA1 genes, one with wild-type levels of functional BRCA1 and one with a mutant BRCA1 gene. We have shown that these cells are differentially sensitive to DNA damage in the form of ionizing radiation. Cells carrying a mutant BRCA1 are more IR-sensitive than their complemented wild-type counterparts. We have begun to perform the synthetic lethal shRNA screen on these two cell lines using our barcoded shRNA library. This strategy should uncover many previously unrecognized targets for therapeutic intervention and has the potential to provide additional, more effective treatment options for BRCA1 mutant breast cancer patients.					
15. SUBJECT TERMS Breast Cancer					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 10	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction	2
Body	3
Key Research Accomplishments	6
Reportable Outcomes	6
Conclusions	6
References	7

Introduction

Women carrying mutations in the *BRCA1* gene, one of two major breast cancer susceptibility genes, have an up to 80% risk of developing breast cancer in their lifetimes¹. These tumors tend to be highly aggressive medullary carcinomas that lack expression of the estrogen or progesterone hormone receptors and amplification of the *HER-2* oncogene^{2,3}. As the most successful current breast cancer treatments target either hormone receptors or *HER-2*, *BRCA1* mutant tumors generally have a poor prognosis compared to other breast cancer subtypes⁴.

The BRCA1 protein is a central component of the cellular pathways involved in the response to DNA damage and control of cell cycle checkpoints⁵⁻⁷. BRCA1 contains two well-defined domains – an N-terminal RING domain, involved in ubiquitylating other proteins, and tandem C-terminal BRCT domains, which mediate interaction with phosphorylated proteins⁸⁻¹⁰. BRCA1 can form three mutually exclusive complexes based on BRCT-mediated interactions with Abraxas (ABRA1), BRIP1 (BACH1) and CTIP¹¹⁻¹³. These BRCA1 interacting proteins recruit additional factors that facilitate the diverse functions of these complexes. The BRCA1-Abraxas complex (BRCA1A) also contains RAP80, BRCC36, BRCC45, and NBA1 (MERIT40)^{11, 14-18}. It is recruited to sites of DNA breaks through RAP80 binding to ubiquitylated proteins formed at breaks by the ubiquitin ligases RNF8 and RNF168¹⁹⁻²¹. The BRCA1A complex regulates the G2-M cell cycle checkpoint by regulating the phosphorylation status of the checkpoint kinase Chk1²². The BRCA1B complex, composed of BRCA1, BRIP1 and TOPBP1, regulates both initiation of DNA replication and activation of the replication stress checkpoint²³⁻²⁵. The BRCA1-CTIP complex (BRCA1C) is required for efficient resection of DNA ends to allow loading of the single stranded DNA binding complex RPA and thus repair through homologous recombination^{26,27}. The numerous functions of BRCA1 complexes highlight the importance of this protein in normal cellular function, and the ways that mutations that interrupt these complexes could lead to tumor formation.

Although *BRCA1* was cloned over 15 years ago, therapeutics that specifically target *BRCA1* mutant cells have not yet been developed. As we discussed in our proposal for this award, we aim to exploit differences between cancer and normal cells to identify new targets for therapeutics that will specifically kill the cancer cells. Tumors can be dependent upon oncogenes harboring gain of function mutations for their survival, which is termed oncogene addiction²⁸. Cancer cells must also cope with increased cellular stresses, such as oxidative stress, DNA damage and aneuploidy, which require an increased dependence on normal cellular stress response pathways. We have termed this dependence on non-oncogenic targets non-oncogene addiction^{29,30}. Both oncogene and non-oncogene addiction pathways are likely to yield therapeutic targets that can be exploited in the treatment of *BRCA1* mutant tumors.

In this award, we proposed using a genetic loss-of-function screen to identify genes that are essential to *BRCA1* mutant cell proliferation and survival. This screen is based on viral shRNA libraries developed in our lab, in collaboration with the lab of Greg Hannon, that target the entire human genome with an average of three shRNAs per gene^{31, 32}.

These libraries can be introduced into cells in a pooled format, allowing for rapid screening of the effects of knock-down of each gene in the genome. In this study, we are introducing the genomic shRNA library into a breast cancer cell line that harbors a homozygous mutation in *BRCA1* that leads to truncation of the protein and loss of a C-terminal BRCT repeat, as well as an isogenic cell line that has been reconstituted for expression of wild-type *BRCA1*. In this manner, we aim to identify and characterize genes that are selectively required for the proliferation and survival of cells expressing mutant BRCA1 protein. These genes, which we call BSLs (for BRCA1 Synthetic Lethal genes), will be prime targets for therapeutics to treat *BRCA1* mutant breast cancers.

Body

Generation of a cloned isogenic pair of breast cancer cell lines

The HCC1937 breast cancer cell line harbors a homozygous mutation in *BRCA1*, 5382insC, which results in truncation of the BRCA1 protein and loss of one of the BRCT repeats³³. These cells are hypersensitive to ionizing radiation and display a defect in repair of DNA double strand breaks^{34,35}. Complementation of these cells with wild-type BRCA1 decreases IR sensitivity and restores normal DNA repair kinetics^{34,35}. In the original proposal, we planned to generate newly complemented cells with a neomycin-selectable wild-type BRCA1 construct, to enable us to use our puromycin-selectable version of the shRNA library. However, difficulty in generating these cells led us to obtain HCC1937 cells from Ralph Scully that were already complemented with BRCA1 and have been previously characterized³⁴. These cells express a bicistronic retroviral construct that contains both wild-type BRCA1 and green fluorescent protein (GFP), which can be used as a marker of retroviral expression. We also obtained HCC1937 cells expressing a GFP-only retrovirus, to control for any effects of retroviral infection or GFP expression.




Figure 1. Expression of reconstituted wild-type BRCA1. Expression of BRCA1 was analyzed in the parental bulk HCC1937-GFP and HCC1937-BRCA1 populations, as well as in several subclones from each population. Two BRCA1 antibodies, MS110 and C20, were used. GFP expression was also assayed. The clones GFP #1 and BRCA1 #1 were selected for use in the screen.

The BRCA1 complemented cells were a polyclonal population that had been selected by fluorescence-activated cell sorting. To ensure that each cell we were infecting with the shRNA library was expressing the same level of BRCA1, we subcloned the cells by limiting dilution to obtain a clonal population of reconstituted cells. We also subcloned the GFP control cells and selected clones with growth kinetics similar to the BRCA1-reconstituted cells. These clones were screened by immunoblotting for expression of both BRCA1 and GFP (Figure 1). The blots were probed with two BRCA1 antibodies, both of which showed a low level of endogenous BRCA1 present in the parental HCC1937 cells and an increased level of BRCA1 in the reconstituted cells. All of the cells expressed similar levels of GFP. A reconstituted clone with high BRCA1 expression was selected for use in the screen, along with a GFP-only expressing clone. To determine whether the BRCA1 reconstitution was functional, we assayed its ability to decrease the IR sensitivity of the HCC1937 cell line. To accomplish this, we performed a colony formation assay, comparing the number of colonies formed on plates that received no treatment to plates that received three gray of gamma irradiation. We found that, indeed, the expression of wild-type BRCA1 in our clonal population was able to rescue the radiation sensitivity of HCC1937 (Figure 2).




Figure 2. Colony survival is increased in clonal population expressing wild-type BRCA1. HCC1937-BRCA1 and HCC1937-GFP clones were plated at 1000 cells/plate and then treated with 3 Gy gamma irradiation or left untreated. Colonies were counted two weeks after irradiation.

Genome-wide shRNA screening for BRCA1 synthetic lethal genes

We are currently performing genome-wide shRNA lethality screens using our isogenic clonal populations of BRCA1-mutant (HCC1937-GFP) and BRCA1-wild-type reconstituted (HCC1937-BRCA1) cells (Figure 3). Our library is divided into six pools of approximately 13,000 shRNAs each. Each pool is introduced into the cell populations in triplicate, at a representation of 1000 cells per shRNA and a multiplicity of infection (MOI) of 1. This ensures that each cell is infected with approximately one shRNA and that each shRNA is introduced into approximately 1000 cells, conditions designed to increase signal and decrease background. Analysis of each pool is carried out in triplicate to increase confidence in the relevance of genes that drop-out in multiple replicates. Following infection, a reference sample is harvested to allow determination of

the initial level of each shRNA in the population. The cells are then selected for expression of the shRNA library and propagated for 8 population doublings, carrying enough cells to maintain the representation of the library in the population. End samples are then harvested, and genomic DNA is prepared from all samples. Once all of the pools are completed, we will generate probes for microarray from each genomic sample by amplifying barcodes built into the shRNA library vector. These probes will be labeled with Cy3 (for the end samples) or Cy5 (for the initial samples), then competitively hybridized to barcode microarrays to determine the change in representation of each shRNA over time. These data will be analyzed using the method of significance analysis of microarrays (SAM) to identify shRNAs that are consistently depleted across triplicates more than two-fold. Genes whose loss of function is synthetically lethal with loss of BRCA1 function will be defined as those targeted by shRNAs that are preferentially lost from the HCC1937-GFP cells, but are maintained in the reconstituted HCC1937-BRCA1 cells.




Figure 3. Schematic of shRNA library screen.

Characterization of BRCA1 synthetic lethal genes

The genes identified from the genome-wide screen as BSLs will be validated individually using multiple shRNAs for each gene. The primary validation assay will be a multi-color competition assay (MCA)³⁶. HCC1937-GFP cells will be infected with an inducible shRNA vector that also inducibly expresses red fluorescent protein (RFP) from the same promoter. These cells will be mixed with mock-infected HCC1937-GFP cells and treated with doxycycline to induce shRNA and RFP expression. After 24 hours of doxycycline treatment, the mixed cells will be analyzed by flow cytometry to determine the initial percentage of RFP positive (and shRNA expressing) cells. These cells will be cultured for several population doublings in doxycycline and then analyzed again by flow

cytometry to determine whether the shRNA expressing cells have decreased as a percentage of the cell population. Those genes that are found to be synthetically lethal with BRCA1 in this assay will be further characterized using gene ontology and databases of proteins that are frequently mutated or overexpressed in cancers to prioritize candidates for further study.

Key Research Accomplishments

- Generation of clonal isogenic BRCA1 wild-type and BRCA1 mutant breast cancer cell lines
- Demonstration of functionality of BRCA1 reconstitution by showing decrease in IR sensitivity
- Beginning genome-wide shRNA library screen in clonal cell lines

Reportable Outcomes

As this study is still at an early stage, no reportable outcomes have been reached.

Conclusions

Identifying novel targets for treatment of *BRCA1* mutant breast cancers has the potential to lead to vastly improved outcomes for patients with these tumors. This screen will allow us to identify and exploit weaknesses in BRCA1-deficient cells that are created by the lack of functional BRCA1 protein. As the cell lines used in this screen are isogenic apart from expression of BRCA1, we will be able to specifically identify genes that are synthetically lethal with BRCA1 mutation and not generally cell lethal. Now that we have appropriate cell lines in hand, we are moving forward with the shRNA library screening and will begin validating candidates as soon as the data is available.

References

1. Narod, S. A. Modifiers of risk of hereditary breast cancer. *Oncogene* 25, 5832-6 (2006).
2. Lakhani, S. R. et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. *Clin Cancer Res* 6, 782-9 (2000).
3. Honrado, E., Osorio, A., Palacios, J. & Benitez, J. Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations. *Oncogene* 25, 5837-45 (2006).
4. Turner, N. C. & Reis-Filho, J. S. Basal-like breast cancer and the BRCA1 phenotype. *Oncogene* 25, 5846-53 (2006).
5. Scully, R. et al. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. *Cell* 90, 425-35 (1997).
6. Huen, M. S., Sy, S. M. & Chen, J. BRCA1 and its toolbox for the maintenance of genome integrity. *Nat Rev Mol Cell Biol* 11, 138-48.
7. Gowen, L. C., Avrutskaya, A. V., Latour, A. M., Koller, B. H. & Leadon, S. A. BRCA1 required for transcription-coupled repair of oxidative DNA damage. *Science* 281, 1009-12 (1998).
8. Ruffner, H., Joazeiro, C. A., Hemmati, D., Hunter, T. & Verma, I. M. Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. *Proc Natl Acad Sci U S A* 98, 5134-9 (2001).
9. Yu, X., Chini, C. C., He, M., Mer, G. & Chen, J. The BRCT domain is a phospho-protein binding domain. *Science* 302, 639-42 (2003).
10. Manke, I. A., Lowery, D. M., Nguyen, A. & Yaffe, M. B. BRCT repeats as phosphopeptide-binding modules involved in protein targeting. *Science* 302, 636-9 (2003).
11. Wang, B. et al. Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. *Science* 316, 1194-8 (2007).
12. Cantor, S. B. et al. BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. *Cell* 105, 149-60 (2001).
13. Yu, X., Wu, L. C., Bowcock, A. M., Aronheim, A. & Baer, R. The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression. *J Biol Chem* 273, 25388-92 (1998).
14. Wang, B., Hurov, K., Hofmann, K. & Elledge, S. J. NBA1, a new player in the Brca1 A complex, is required for DNA damage resistance and checkpoint control. *Genes Dev* 23, 729-39 (2009).
15. Sobhian, B. et al. RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. *Science* 316, 1198-202 (2007).
16. Kim, H., Chen, J. & Yu, X. Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. *Science* 316, 1202-5 (2007).
17. Chen, X., Arciero, C. A., Wang, C., Broccoli, D. & Godwin, A. K. BRCC36 is essential for ionizing radiation-induced BRCA1 phosphorylation and nuclear foci formation. *Cancer Res* 66, 5039-46 (2006).

18. Dong, Y. et al. Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair. *Mol Cell* 12, 1087-99 (2003).
19. Mailand, N. et al. RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. *Cell* 131, 887-900 (2007).
20. Doil, C. et al. RNF168 binds and amplifies ubiquitin conjugates on damaged chromosomes to allow accumulation of repair proteins. *Cell* 136, 435-46 (2009).
21. Stewart, G. S. et al. The RIDDLE syndrome protein mediates a ubiquitin-dependent signaling cascade at sites of DNA damage. *Cell* 136, 420-34 (2009).
22. Yarden, R. I., Pardo-Reoyo, S., Sgagias, M., Cowan, K. H. & Brody, L. C. BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. *Nat Genet* 30, 285-9 (2002).
23. Greenberg, R. A. et al. Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes. *Genes Dev* 20, 34-46 (2006).
24. Kumaraswamy, E. & Shiekhattar, R. Activation of BRCA1/BRCA2-associated helicase BACH1 is required for timely progression through S phase. *Mol Cell Biol* 27, 6733-41 (2007).
25. Makiniemi, M. et al. BRCT domain-containing protein TopBP1 functions in DNA replication and damage response. *J Biol Chem* 276, 30399-406 (2001).
26. Yun, M. H. & Hiom, K. CtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle. *Nature* 459, 460-3 (2009).
27. Schlegel, B. P., Jodelka, F. M. & Nunez, R. BRCA1 promotes induction of ssDNA by ionizing radiation. *Cancer Res* 66, 5181-9 (2006).
28. Weinstein, I. B. Cancer. Addiction to oncogenes--the Achilles heel of cancer. *Science* 297, 63-4 (2002).
29. Solimini, N. L., Luo, J. & Elledge, S. J. Non-oncogene addiction and the stress phenotype of cancer cells. *Cell* 130, 986-8 (2007).
30. Luo, J., Solimini, N. L. & Elledge, S. J. Principles of cancer therapy: oncogene and non-oncogene addiction. *Cell* 136, 823-37 (2009).
31. Paddison, P. J. et al. A resource for large-scale RNA-interference-based screens in mammals. *Nature* 428, 427-31 (2004).
32. Silva, J. M. et al. Second-generation shRNA libraries covering the mouse and human genomes. *Nat Genet* 37, 1281-8 (2005).
33. Tomlinson, G. E. et al. Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. *Cancer Res* 58, 3237-42 (1998).
34. Scully, R. et al. Genetic analysis of BRCA1 function in a defined tumor cell line. *Mol Cell* 4, 1093-9 (1999).
35. Cortez, D., Wang, Y., Qin, J. & Elledge, S. J. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. *Science* 286, 1162-6 (1999).
36. Smogorzewska, A. et al. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. *Cell* 129, 289-301 (2007).